MEI reports 90% ORR in Phase Ib of ME-401 in hematologic malignancies

MEI Pharma Inc. (NASDAQ:MEIP) reported updated data from 30 evaluable patients with relapsed or refractory follicular lymphoma or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in a Phase Ib trial showing that once-daily ME-401 led to an objective response rate (ORR) of 90%. In 21 patients with follicular lymphoma, the ORR was 86%. In nine patients with CCL/SLL, the ORR was 100%. The data were presented at the American Society of Clinical Oncology meeting in Chicago.

In an abstract released ahead of ASCO, MEI reported that ME-401 led to an ORR of 83% in 29 evaluable patients (see BioCentury, June 1)...